- Home
- VCYT vs RARE Comparison
VCYT vs RARE Comparison
Compare VCYT & RARE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | VCYT | RARE |
|---|---|---|
| Founded | 2006 | 2010 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.6B | 2.1B |
| IPO Year | 2013 | 2013 |
Fundamental Metrics
Financial Performance| Metric | VCYT | RARE |
|---|---|---|
| Price | $32.85 | $24.87 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 7 | 20 |
| Target Price | $44.00 | ★ $59.10 |
| AVG Volume (30 Days) | 551.5K | ★ 1.5M |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 164.52 | 7.31 |
| EPS | ★ 0.82 | N/A |
| Revenue | N/A | ★ $673,000,000.00 |
| Revenue This Year | $13.76 | $13.12 |
| Revenue Next Year | $12.35 | $37.80 |
| P/E Ratio | $41.10 | ★ N/A |
| Revenue Growth | N/A | ★ 20.13 |
| 52 Week Low | $22.61 | $18.29 |
| 52 Week High | $50.71 | $40.17 |
Technical Indicators
Market Signals| Indicator | VCYT | RARE |
|---|---|---|
| Relative Strength Index (RSI) | 48.26 | 59.88 |
| Support Level | $31.00 | $23.69 |
| Resistance Level | $34.37 | $25.70 |
| Average True Range (ATR) | 1.38 | 1.00 |
| MACD | 0.01 | -0.02 |
| Stochastic Oscillator | 46.43 | 47.31 |
Price Performance
Historical ComparisonAbout VCYT Veracyte Inc.
Veracyte Inc is a genomic diagnostics company. The group empowers clinicians with the insights necessary to guide and assure patients at pivotal moments in the race to diagnose and treat cancer. It offers tests for prostate cancer (Decipher Prostate), thyroid cancer (Afirma), breast cancer (Prosigna), and bladder cancer (Decipher Bladder).
About RARE Ultragenyx Pharmaceutical Inc.
Ultragenyx Pharmaceutical Inc is a USA-based biopharmaceutical company. The company identifies, acquires, develops, and commercializes novel products for the treatment of serious, rare, and ultra-rare diseases, with a focus on debilitating genetic conditions. Its medicine portfolio includes Crysvita, Dojolvi, and Mepsevii. Crysvita is indicated for the treatment of X-linked hypophosphatemia (XLH) in adult and pediatric patients aged one year and older. Mepsevii is indicated for pediatric and adult patients for the treatment of Mucopolysaccharidosis VII. The company operates across North America, Latin America, Europe, the Middle East and Africa, and Asia-Pacific, with the majority of its revenue generated from North America.